SCHEMBL20113017

SCHEMBL20113017

C/C=C\CNc1ccncc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSD P07339 1/20 0.41
BCHE P06276 1/20 0.39
MDM2 Q00987 1/20 0.39
FDPS P14324 1/20 0.38
RAB9A P51151 2/20 0.37
HDAC3 O15379 1/20 0.36
HDAC4 P56524 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC7 Q8WUI4 1/20 0.36
HDAC2 Q92769 1/20 0.36
HDAC10 Q969S8 1/20 0.36
HDAC11 Q96DB2 1/20 0.36
HDAC8 Q9BY41 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
HDAC9 Q9UKV0 1/20 0.36
HDAC5 Q9UQL6 1/20 0.36
L3MBTL1 Q9Y468 2/20 0.35
KDM4E B2RXH2 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
LMNA P02545 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9174077 1.00 CTSD (0.41) CTSDBCHEMDM2FDPSRAB9A
SCHEMBL2967975 0.84 MAPT (0.39) POLB
SCHEMBL2967974 0.84 MAPT (0.39) POLB
SCHEMBL16905688 0.78 MAPT (0.44) CTSDHDAC3L3MBTL1KMT2A
SCHEMBL9668035 0.78 MAPT (0.44) CTSDHDAC3L3MBTL1KMT2A
SCHEMBL2350761 0.78 MAPT (0.44) CTSDHDAC3L3MBTL1KMT2A
SCHEMBL11325703 0.77 MAPT (0.54) RAB9AHDAC3HDAC4HDAC1HDAC7
SCHEMBL11325700 0.77 MAPT (0.54) RAB9AHDAC3HDAC4HDAC1HDAC7
SCHEMBL112295 0.74 MDM2 (0.46) CTSDBCHEMDM2FDPSRAB9A
SCHEMBL1150196 0.74 KDM4E (0.51) CTSDBCHEMDM2FDPSRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180117060-A1 COMBINATION OF CATALYTIC MTORC 1/2 INHIBITORS AND SELECTIVE INHIBITORS OF AURORA A KINASE MILLENNIUM PHARM INC (US) 2018-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180117060-A1 COMBINATION OF CATALYTIC MTORC 1/2 INHIBITORS AND SELECTIVE INHIBITORS OF AURORA A KINASE AURKC, MTOR, AURKA CTSD 2687/4885BCHE 4428/4885MDM2 933/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.